<DOC>
	<DOCNO>NCT00428935</DOCNO>
	<brief_summary>The purpose study determine safety miniature dystrophin gene treatment progressive muscle weakness due Duchenne Muscular Dystrophy ( DMD ) .</brief_summary>
	<brief_title>Safety Study Mini-dystrophin Gene Treat Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>This phase I randomize double blind dose escalation study investigate safety efficacy mini-dystrophin gene transfer biceps muscle Duchenne muscular dystrophy patient , age 5 12 year age , use recombinant adeno-associated virus . Eligible participant must know dystrophin gene mutation may concurrently treat corticoid steroid . The mini-dystrophin gene placebo agent ( normal saline empty viral capsid ) inject directly biceps muscle conscious sedation . Following gene transfer , patient admit hospital 48 hour observation follow weekly outpatient visit Columbus Children 's Hospital Neuromuscular Clinic . A bilateral muscle biopsy preform follow 6 week long term follow consist bi-annual visit next 2 year .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Known null mutation Dystrophin gene Male age 5 year old If taking corticosteroid , must dose unchanged past 3 month Serum creatine kinase elevation great 10x normal value ( establish Children 's Hospital ) Progressive , symmetrical proximal muscle weakness arm legs Unable cooperate muscle strength test Joint contracture prohibit muscle strength test Concomitant illness Individuals predispose excessive vagal response ( bradyarrhythmia hypotension ) Controlled substance abuse</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Duchenne</keyword>
	<keyword>Muscle</keyword>
	<keyword>Muscular Dystrophy</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Dystrophin</keyword>
	<keyword>Adeno-Associated Virus</keyword>
	<keyword>AAV</keyword>
</DOC>